Russia seeks Chinese companies to increase production of Sputnik-V


New Delhi: In the midst of the 2nd Covid Wave of Coronavirus in India, Russia has approached China to increase its vaccine production. According to a report by the global news agency AP, during the past few weeks, Russia has entered into agreements with several Chinese companies to produce 26 million doses of vaccine. It is said that with this decision, Russia will now be able to rapidly fulfill orders in Latin America, the Middle East, Africa.

In August 2020, Russia first announced the development of corona vaccine. The vaccine was named Sputnik-V. Concerns were initially raised globally about its trial data. But some time ago, the British Medical Journal Lancet published a study on the data of this vaccine. The study stated that the effectiveness rate of this vaccine is 91 percent and during extensive use, it has been revealed that the vaccine is completely safe.


The vaccine in Emergency Use in India
Explain that amidst the shortage of corona vaccine in India, Russia’s Sputnik vaccine reached India last Saturday. The arrival of the Sputnik vaccine in India will accelerate the third phase of vaccination. The third phase of vaccination for people aged 18 to 44 in India has started on May 1. A large number of people have registered for the third phase.

The Sputnik-V vaccine has been developed by the Gamalaya National Research Institute of Epidemiology and Microbiology. Sputnik V is a two-dose vaccine. The second dose must be taken on the 21st day after taking the first dose.
Between the 28th and 42nd day of vaccination, the body will develop immunity against the coronavirus.